BARD C R INC (BCR)
US0673831097
Amazon's Health Care Push Could Be Its Next Big Market Disruption
The growth of Amazon stock could be sustained for years if the company continues its foray into the health care industry, where it could be a disrupter.
BD Completes Bard Acquisition, Creating New Global Health Care Leader
Huntington Ingalls Industries Set to Join S&P 500; Scientific Games to Join S&P MidCap 400 and Ultra Clean Holdings to Join S&P SmallCap 600
BD Statement On MOFCOM Clearance Of Bard Acquisition
BD Statement On FTC Clearance Of Bard Acquisition
CR Bard (BCR) a Strong Buy on Exceptional Quant Score
Currently, CR Bard Inc (NYSE:BCR) has a Strong Buy using Louis Navellier's investing methodology and his Portfolio Grader stock evaluator. This represents no change from the previous week and is the same ranking BCR has had from Portfolio Grader for 3 months.
CR Bard (BCR) a Strong Buy on Outstanding Quant Score
CR Bard Inc (NYSE:BCR) is a $24.3 billion in market value constituent of the Health Care Equipment & Supplies GICS industry group where the stock's Portfolio Grader ranking places it 22 among the 161 companies in this industry group, placing it among the leaders. BCR is ranked among the sector leaders with a ranking of 64 among the 781 companies in the sector and number 364 in the 5000 company Portfolio Grader company universe.
BD Statement On Merit Medical Agreement To Purchase BD, Bard Product Lines
CR Bard (BCR) a Strong Buy on Top-End Quant Score
Currently, CR Bard Inc (NYSE:BCR) has a Strong Buy using the system of Louis Navellier for investing and his Portfolio Grader stock evaluator. The current Portfolio Grader recommendation on the shares has been in place for 3 months.
CR Bard (BCR) a Strong Buy on Top-End Quant Score
Portfolio Grader currently ranks CR Bard Inc (NYSE:BCR) a Strong Buy. The methods for investing incorporated in this analytical tool developed by Louis Navellier evaluates and ranks nearly 5,000 stocks each week from a fundamental and quantitative perspective. BCR has maintained this ranking for 3 months.
C.R. Bard, Inc. Common Stock (BCR): PT Raised News
BCR – Barclays raises PT to $337 from $245. This new price target represents a 0.94% upside over the stock’s previous closing price of $333.86.
C.R. Bard, Inc. Common Stock (BCR): Neutral Rating Reiterated
BCR – Cowen & Company reiterates Hold rating, $317 PT. This price target represents a -5.05% downside over the stock’s previous closing price of $333.86.
Cowen & Co. Sticks to Its Hold Rating for CR Bard
In a report released yesterday, Doug Schenkel from Cowen & Co. reiterated a Hold rating on CR Bard (NYSE: BCR), with a price target of $317. The company’s shares opened today at $333.86, close to its 52-week high of $335.84. According to TipRanks.com, Schenkel is a 4-star analyst with an average return of 3.8% and
The post Cowen & Co. Sticks to Its Hold Rating for CR Bard appeared first on Analyst Ratings.
C.R. Bard, Inc. Common Stock (BCR): Neutral Rating Reiterated
BCR – Needham & Co. reiterates Hold rating. Stock price at the time of this analyst call was $328.03.
Needham Sticks to Their Hold Rating for CR Bard
In a report released today, Michael Matson from Needham maintained a Hold rating on CR Bard (NYSE: BCR). The company’s shares closed yesterday at $328.03, close to its 52-week high of $330.31. Matson wrote: “BCR’s 3Q17 revenue missed and EPS beat consensus and management raised its 2017 revenue and EPS guidance. Revenue growth slowed somewhat
The post Needham Sticks to Their Hold Rating for CR Bard appeared first on Analyst Ratings.
C.R. Bard, Inc. Common Stock (BCR): Earnings News
BCR – Beats Wall Street consensus EPS estimates by $0.06. Revenues in-line.
Bard Announces Third Quarter Results
BD Statement On European Commission Conditional Clearance Of Bard Acquisition
Stock Performance Review on Medical Supplies Industry -- Microbot Medical, Cooper, Waters, and C.R. Bard
Bard Declares Quarterly Dividend
C.R. Bard, Inc. Common Stock (BCR): Neutral Rating Reiterated
BCR – Jefferies reiterates Hold rating, $317 PT. This price target represents a -1.03% downside over the stock’s previous closing price of $320.30.
CR Bard Gets a Hold Rating from Jefferies
In a report issued on September 12, Michael Yee from Jefferies reiterated a Hold rating on CR Bard (NYSE: BCR), with a price target of $317. The company’s shares opened today at $319.79, close to its 52-week high of $324.58. According to TipRanks.com, Yee is a 5-star analyst with an average return of 11.3% and
The post CR Bard Gets a Hold Rating from Jefferies appeared first on Analyst Ratings.
How Hurricanes Harvey and Irma are affecting health care companies
Hurricane Matthew cost one hospital chain alone millions of dollars last year.
Daily Technical Summary Reports on Medical Supplies Stocks -- Insulet, Microbot Medical, C.R. Bard, and Hill Rom
C.R. Bard, Inc. Common Stock (BCR): Product News News
BCR – Granted premarket approval by the FDA for the LUTONIX 035 Drug Coated Balloon PTA Catheter for a new indication.
C.R. Bard, Inc. Common Stock (BCR): Hedge Fund News
BCR – Adage Capital top new buy.
Archer Daniels Midland Takes Over #224 Spot From Bard
In the latest look at the underlying components of the S&P 500 ordered by largest market capitalization, Archer Daniels Midland Co. (ADM) has taken over the #224 spot from Bard Inc (BCR), according to The Online Investor..
Becton Dickinson and Co Faces a Rough Comparator
Bard Shareholders Approve Proposed Merger With Becton, Dickinson
Healthcare Stock Performance Review -- Endologix, Zimmer Biomet, Insulet, and C.R. Bard
These 25 stocks in the S&P 500 just hit record highs
Apple was the big winner, but companies in various industries made the list of winners.
Tech And Healthcare Lead A Surging Market To New Heights
Technology and Healthcare sectors continue to be the year-to-date leaders, and lately Utilities has gotten into the act on an income play as interest rates stay low.
These 25 stocks in the S&P 500 just hit record highs
Apple was the big winner, but companies in various industries made the list of winners.
C.R. Bard, Inc. Common Stock (BCR): Neutral Rating Reiterated
BCR – Jefferies reiterates Hold rating. Stock price at the time of this analyst call was $322.53.
Analysts Offer Insights on Healthcare Companies: CR Bard (NYSE: BCR), Lantheus (NASDAQ: LNTH) and Neurocrine (NASDAQ: NBIX)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on CR Bard (NYSE: BCR), Lantheus (NASDAQ: LNTH) and Neurocrine (NASDAQ: NBIX). CR Bard (NYSE: BCR) In a report issued on August 1, Anthony Petrone from Jefferies reiterated a Hold rating on CR Bard (NYSE: BCR), with a price
The post Analysts Offer Insights on Healthcare Companies: CR Bard (NYSE: BCR), Lantheus (NASDAQ: LNTH) and Neurocrine (NASDAQ: NBIX) appeared first on Analyst Ratings.
EY's Greene Sees More Med Tech, CRO Deals Ahead
C.R. Bard, Inc. Common Stock (BCR): Corp. News News
BCR – Discloses that civil investigative demand was served by the Department of Justice in July.